Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Avacta Group (AVCT) Share News

SUMMARY: London listings with exposure to Silicon Valley Bank

13th Mar 2023 12:18

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

17th Jan 2023 16:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

Avacta raises GBP64 million to finance Launch Diagnostics purchase

8th Nov 2022 13:51

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million. Read More

Avacta plans to raise GBP62 million; buys Launch Diagnostics

18th Oct 2022 12:40

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million. Read More

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

29th Sep 2022 11:30

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division. Read More

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

5th Sep 2022 11:07

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More

Avacta shares up as drug approved for soft tissue sarcoma treatment

5th Sep 2022 10:10

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma. Read More

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

1st Sep 2022 12:01

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort. Read More

Avacta joint venture completes funding for lead cell therapy programme

21st Jul 2022 12:17

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round. Read More

Avacta's partner LG Chem renews licence to develop Affimer platform

30th Jun 2022 11:22

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta. Read More

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

29th Jun 2022 11:38

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

29th Jun 2022 10:21

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort. Read More

UK shareholder meetings calendar - next 7 days

16th Jun 2022 16:03

Read More

IN BRIEF: Avacta joint venture expands partnership with GenScript

16th May 2022 14:04

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing. Read More

Avacta increases shareholding in drug developer AffyXell to 22%

13th Apr 2022 17:33

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics. Read More

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

8th Apr 2022 11:28

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More

Avacta joint venture to collaborate with Chinese biological company

8th Apr 2022 10:37

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs. Read More

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

6th Apr 2022 10:23

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends. Read More

Avacta sells veterinary division to Vimian for up to GBP2.3 million

16th Mar 2022 11:38

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB. Read More

Avacta shares up 12% after chemotherapy drug advances to next stage

3rd Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage Read More

FTSE 100 Latest
Value9,506.12
Change14.87